Transgene Provides Business and Financial Update for Q1 2026

information fournie par Boursorama CP •29/04/2026 à 17:45

- Enrolment completed in Phase 2 part of head and neck cancer clinical trial (TG4050) – Topline data expected by the end of Q1 2028 as per plan
- Phase 1 data from TG4050 in head and neck cancer published on medRxiv
- License agreement signed with NEC Bio to advance clinical development of TG4050 in head and neck cancer
- Financial visibility until early 2028


Strasbourg, France, April 29, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provides a business update on its myvac® platform, and its individualized neoantigen therapeutic vaccine (INTV) TG4050, and upcoming plans, including its financial position as of March 31, 2026.

.../...